305 Frequency and acceptance of CDSS-generated STOPP/START signals - SI Table SI1.1. Continued. STOPP criteria (n=79) All countries Belgium (BE) Switzerland (CH) Ireland (IE) The Netherlands (NL) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) H 2. NSAID with severe hypertension (risk of exacerbation of hypertension) or severe heart failure 40 57.5% 8 50.0% 28 53.6% 1 100% 3 100% C 9. Vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors for first pulmonary embolus without continuing provoking risk factor s (e.g. thrombophilia) for > 12 months 37 2.7% 3 0% 24 4.2% 4 0% 6 0% G 3. Anti-muscarinic bronchodilators (e.g. ipratropium, tiotropium) with a history of narrow angle glaucoma or bladder outflow obstruction 35 17.1% 3 0% 21 9.5% 0 N/A 11 36.4% H 5. Corticosteroids (other than periodic intraarticular injections for mono-articular pain) for osteoarthritis 32 15.6% 6 16.7% 13 30.8% 5 0% 8 0% G 4. Benzodiazepines with acute or chronic respiratory failure i.e. pO2 < 8.0 kPa ± pCO2 > 6.5 kPa 31 58.1% 4 50.0% 18 61.1% 0 N/A 9 55.6% B 4. Beta blocker with bradycardia (< 50/min) , type II heart block or complete heart block 28 10.7% 1 0% 25 12.0% 1 0% 1 0.0% K 1. Benzodiazepines (in patients with risk of falls) 27 74.1% 2 50.0% 9 44.4% 6 83.3% 10 100% B 8. Thiazide diuretic with current significant hypokalaemia (i.e. serum K+ < 3.0 mmol/l), hyponatraemia (i.e. serum Na+ < 130 mmol/l) hypercalcaemia (i.e. corrected serum calcium > 2.65 mmol/l) or with a history of gout 22 54.5% 2 50.0% 13 46.2% 2 50.0% 5 80.0% 4
RkJQdWJsaXNoZXIy MTk4NDMw